Amgen is advancing its obesity treatment, MariTide, targeting a burgeoning global obesity drug market projected to reach nearly $95 billion by 2030. The drug aims to differentiate itself with a single autoinjector dose that can be administered monthly, in contrast to competitors from Eli Lilly and Novo Nordisk, which require weekly injections. Initial phase II trials indicate average weight loss of approximately 20% over 52 weeks for patients without type II diabetes and 17% for those with diabetes.
Amgen’s MARITIME phase III program includes nine global studies assessing MariTide for obesity, type II diabetes, and related conditions, with future plans for three additional studies starting in 2026. A phase III switch study will also investigate patients transitioning from weekly treatments to MariTide’s less frequent dosing schedule, potentially cutting the frequency of injections from 52 to as few as four annually.
Despite MariTide’s advantages, Amgen faces significant competition from established players like Lilly and Novo Nordisk, which have a strong market presence and newer therapies showing greater weight-loss efficacy, including Lilly’s retatrutide, which reports approximately 28% weight loss. Nonetheless, the vast obesity market may support multiple entrants, giving Amgen the opportunity to capture a share even with a modest market performance.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
